Khosla Ventures

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

Founded in 2016, Rejuvenation Technologies is a biotechnology company based in Mountain View, California. It specializes in developing nucleoside-modified TERT mRNA to safely extend telomeres for human health extension.

Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.

Carver Biosciences is a biotechnology company developing antiviral therapies that target RNA viruses, including CRISPR/Cas13-based approaches. Its work centers on RNA-level interventions designed to destroy respiratory viruses and prevent their replication, with the aim of providing therapeutics that complement vaccination and other antiviral measures. The company seeks to arrest the progression of infection and offer ready alternative treatments for patients facing RNA virus–related diseases.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.

Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.

Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in engineering and developing innovative tools for biological automation, focusing on scalable automation solutions for genetic engineering. Its platform is designed to revolutionize genomics research by providing affordable genomic sample preparation and automation for complex biological workflows. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs aims to streamline sample processing and enhance the capabilities of biotech organizations in the next generation of genomic automation.

Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.

Pearl Bio is a synthetic biology company that leverages its proprietary platform to create novel biologics and biomaterials. By engineering genomes and ribosomes, the company enables scientists to explore diverse chemistries and advance treatments for genetic or acquired diseases.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Probably Genetic is a company that provides genetic testing services to diagnose rare genetic conditions, including those often initially misdiagnosed as autism spectrum disorder. It enables at-home saliva sample collection and performs comprehensive DNA sequencing analysis, accompanied by personalized counseling to help patients and families obtain accurate diagnoses and access relevant clinical treatments. By offering educational materials and streamlined testing, the company aims to shorten diagnostic journeys and support individuals who fall through gaps in the healthcare system.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

Loop Genomics develops long-read DNA sequencing technology that enables existing short-read instruments to perform high-throughput, phased, single-molecule sequencing. The company provides consumables and analysis tools to extend sequencing capabilities across research, diagnostics, agriculture-biotech, and industrial applications, allowing laboratories to access long-read sequencing without new platforms. Its technology supports full-length, phased sequencing of microbial communities to improve microbiome profiling by capturing all variable regions, and enables accurate phased sequencing of human leukocyte antigen genes to reduce diploid ambiguity for transplantation testing and association studies. In virology, it maps viral genetic variability at the quasi-species level to identify mutations and inform therapy and vaccine strategies. By delivering high-throughput, phased data with existing infrastructure, Loop Genomics clarifies complex genetic signals.

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

BioConsortia is an agricultural biotechnology company that discovers, develops, and commercializes microbial consortia products for enhancing crop yields. Using its proprietary Advanced Microbial Selection process, the company selects beneficial microbes to improve fertilizer utilization, plant growth, and other desirable traits such as abiotic tolerance and enhanced metabolite expression. BioConsortia's products are designed for application as seed treatments and soil additives.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Ontera develops handheld diagnostic platforms using silicon nanopore chips and proprietary biochemistry. These platforms detect and differentiate single molecules in DNA, RNA, proteins, viruses, antibodies, and other analytes from various life forms. Applications include human and animal diagnostics, agriculture, food safety testing, environmental monitoring, and more.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

BioConsortia is an agricultural biotechnology company that discovers, develops, and commercializes microbial consortia products for enhancing crop yields. Using its proprietary Advanced Microbial Selection process, the company selects beneficial microbes to improve fertilizer utilization, plant growth, and other desirable traits such as abiotic tolerance and enhanced metabolite expression. BioConsortia's products are designed for application as seed treatments and soil additives.

Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

20n is a biotechnology company that focuses on engineering microbes through advanced algorithms to produce valuable chemicals for therapeutic and industrial applications. Their innovative technology has successfully demonstrated the ability to create bacteria capable of synthesizing Paracetamol, a widely used pain reliever, representing a significant breakthrough in bioproduction methods. Additionally, 20n is developing an open-source platform that allows users to predict DNA edits and design custom fermentation organisms, facilitating the discovery of new molecules and more efficient production processes. The company's data mining capabilities further enhance their potential to identify and produce a wide spectrum of biologically-derived chemicals, positioning them at the forefront of synthetic biology and biomanufacturing.

Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.

BioConsortia is an agricultural biotechnology company that discovers, develops, and commercializes microbial consortia products for enhancing crop yields. Using its proprietary Advanced Microbial Selection process, the company selects beneficial microbes to improve fertilizer utilization, plant growth, and other desirable traits such as abiotic tolerance and enhanced metabolite expression. BioConsortia's products are designed for application as seed treatments and soil additives.

NewLimit focuses on developing epigenetic reprogramming medicines to treat age-related diseases and extend the human health span. It uses single-cell genomics, machine learning, and functional assays to identify epigenetic targets and develop messenger RNA-based therapies for improving metabolic function in liver cells.